Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $17.85 is 197.50% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 18.04||$ 18.87|
|Low:||$ 17.59||$ 6|
ETFs with VCEL as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|0.71%||Invesco Wilshire Micro-Cap ETF (WMCR)||-6.38 (-17.21%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
Vericel Corporation is a leader in advanced cell therapies for the sports medicine and severe burn care markets, and a developer of patient-specific expanded cell therapies for use in the treatment of patients with severe diseases and conditions. We currently have two marketed autologous cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults that was approved by the U.S. Food and Drug Administration (FDA) on December 13, 2016. The first shipment and implantation of MACI occurred on January 31, 2017. At the end of the second quarter, we removed MACI's predecessor, Carticel® (autologous cultured chondrocytes), from the market. ... More ...
Nasdaq Official Price
Jan. 16, 2019
Jan. 15, 2019